Nuveen’s Gilead Sciences GILD Stock Holding History

Nuveen’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,000	Closed	-$748K	–	3311
2020 Q1	$748K	Buy	+10,000	New	+$691K	﹤0.01%	2631

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen's GILD Position: Q1 2026 in Review

Nuveen increased its Gilead Sciences (GILD) stake by 24% in Q1 2026, buying an estimated $213M and bringing the position to 7,833,564 shares worth $1.09B. The position accounts for 0.3% of the portfolio, ranked #65.

Nuveen first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,315 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Nuveen held 7,833,564 shares of Gilead Sciences worth $1.09B as of Q1 2026.
Nuveen bought 1,519,508 Gilead Sciences shares in Q1 2026, an estimated $213M.
Gilead Sciences made up 0.3% of Nuveen's portfolio in Q1 2026, its #65 holding.
Nuveen first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
2,315 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.